Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer ’s Disease
CAMBRIDGE, Mass. and TOKYO, July 08, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news